Genmab first-half revenues rise 16%, but operating profit falls 21%

9 August 2018

Danish biotech firm Genmab (OMX: GEN) has released its financial results for the first half of 2018, showing that revenues for the period were up 16% at 1.19 billion Danish kroner ($184.9 million), but operating income at 459 million kroner was down 21%, driven by increased operating expenses, which was partly offset by higher revenue.

The company’s shares dipped 1.8% to 1,060.50 kroner by close of trading yesterday and dropped a further 3.5% to 1,023.50 kroner this morning.

The revenue increase was mainly driven by the payment from Novartis of $50 million, under a collaboration on Arzerra (ofatumumab), and higher Darzalex (daratumumab) royalties, partly offset by a decrease in Darzalex milestones. Darzalex’ net sales were $943 million, resulting in royalty income of 695 million kroner. Johnson & Johnson (NYSE: JNJ) subsidiary Janssen has an exclusive worldwide license to develop, manufacture and commercialize the drug.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK